New combo attack on spreading cancer shows early promise
NCT ID NCT07269080
Summary
This early-stage study is testing whether adding targeted, high-dose radiation to standard immunotherapy can better control advanced solid tumors that have spread to multiple sites. It will enroll about 28 patients whose cancer has spread to 3-10 locations and who are already on immunotherapy. The main goal is to see if this combination causes a significant drop in cancer DNA in the blood, which could signal the treatment is working.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Illinois at Chicago
RECRUITINGChicago, Illinois, 60612, United States
Contact
Conditions
Explore the condition pages connected to this study.